Orexin A (human, rat, mouse)

Research use only, not for human use.

Orexin A human, rat, mouse, a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A human, rat, mouse has been used to study its effect on the functioning of porcine pancreatic islets. It has also been used as an orexin receptor 1 (OX1R) antagonist to study the effect of orexin systems in the effect of etonogestrel on respiratory response to prolonged metabolic acidosis.

Orexin A human, rat, mouse, a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A human, rat, mouse has been used to study its effect on the functioning of porcine pancreatic islets. It has also been used as an orexin receptor 1 (OX1R) antagonist to study the effect of orexin systems in the effect of etonogestrel on respiratory response to prolonged metabolic acidosis.(In Vitro):Orexin A human, rat, mouse has high affinity for OX1R, with 38 nM IC50 and 34 nM EC50 values in the the [Ca2﹢]i transient assay.(In Vivo):Orexin A human, rat, mouse (3-30 mg/kg; i.v.; 5 min pre-test) significantly increases the latency to response at 10 and 30 mg/kg i.v. when given 5 min pre-test from 24.8±2.0 s in vehicle-treated mice to 35.0±3.7 s and 45.7±4.5 s, respectively. Orexin A human, rat, mouse (3, 10 and 30 mg/kg; i.v.) was given immediately before phenylp-quinone (PPQ) and increases the latency to the first PPQ-induced constriction from 357.4±35.2 s in vehicle-treated mice to 500.3±31.2 s at 10 mg/kg and 594.5±5.5 s at 30 mg/kg.

Orexin A (human, rat, mouse) has high affinity for OX1R, with 38 nM IC50 and 34 nM EC50 values in the the [Ca2﹢]i transient assay.

Orexin A (human, rat, mouse) (3-30 mg/kg; i.v.; 5 min pre-test) significantly increases the latency to response at 10 and 30 mg/kg i.v. when given 5 min pre-test from 24.8±2.0 s in vehicle-treated mice to 35.0±3.7 s and 45.7±4.5 s, respectively. Orexin A (human, rat, mouse) (3, 10 and 30 mg/kg; i.v.) was given immediately before phenylp-quinone (PPQ) and increases the latency to the first PPQ-induced constriction from 357.4±35.2 s in vehicle-treated mice to 500.3±31.2 s at 10 mg/kg and 594.5±5.5 s at 30 mg/kg. Animal Model:Female mice (mouse carrageenan-induced thermal hyperalgesia test)Dosage:3, 10 and 30 mg/kg Administration:i.v.; 5 min pre-test Result:Significantly increased the latency to response at 10 and 30 mg/kg.

——

Others

Other Targets

——

——

——

205640-90-0

3561.1

C152H243N47O44S4

>98% (HPLC)

In Vitro:?H2O : ≥ 50 mg/mL (14.04 mM)

——

Sequence:{Glp}-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-IIE-Leu-Thr-Leu-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14)

(-20℃)

With Ice Pack

≥ 2 years